bpc 157 fda news 2025 to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters FDA's Overreach on Compounded Peptides

At this time, I currently do not recommend my patients take BPC 157

The prevalence of neuropathic pain in the general population assessed via validated questionnaires can reach 10%, representing a significant disease burden [11]

1 In patients from the Asian region (excluding Australia), the median progression-free survival (PFS) was 20.4 months for glofitamab plus gemcitabine and oxaliplatin versus 2 months for rituximab plus gemcitabine and oxaliplatin

It may be hypothesized that COX-2 products may have a protective role (i.e., explaining the lack of efficacy of COX-2 inhibition [98]), which is in fact a spontaneous response against injury [99]

BPC 157 Capsules 4 products BPC-157 Arginate Salt, 500mcg per capsule